Biotech News

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines (RVMD)ir.revmed.com2026-05-07 04:12 ESTClinical readout

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Revolution Medicines

Revolution Medicines is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

RVMDRevolution Medicines2026-05-31 16:16:35 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-05-22 00:08:27 EST

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

RVMDRevolution Medicines2026-05-07 02:01:52 EST

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

RVMDRevolution Medicines2026-05-06 18:46:39 EST

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States